MAT Training: Methadone and buprenorphine on March 11
clinical impact of drug interactions
PCSS-MAT is a national training and mentoring project developed in response to the prescription opioid misuse epidemic and the availability of newer pharmacotherapies to address opioid dependence.
Methadone and Buprenorphine: Clinical Impact of Drug Interactions
Elinore McCance-Katz, MD, PhD
Chief Medical Officer
Substance Abuse and Mental Health Services Administration
Tuesday, March 11, 2014
Noon – 1 p.m. Eastern
Drug-drug interactions between opioid medications used to treat opioid use disorder, such as methadone and buprenorphine, and medications for treating co-occurring physical or mental health conditions can be a source of morbidity and mortality.
This presentation will briefly review the epidemiologic data on drug-drug interactions that include methadone or buprenorphine and discuss the physiological basis for such interactions including pharmacokinetic and/or pharmacodynamics interactions. It will also review drug-drug interactions and clinical consequences using a series of case studies that address questions related to issues of drug interactions in practice.
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Psychiatric Association designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The PCSS-MAT is a collaboration of: American Academy of Addiction Psychiatry (lead), American Psychiatric Association, American Osteopathic Academy of Addiction Medicine, and the American Society of Addiction Medicine. Funding for this initiative was made possible (in part) by Physicians' Clinical Support System for Medication Assisted Treatment (1U79TI024697) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.